Clinical Tagline:
Localized modulation of neutrophil elastase-driven airway destruction in cystic fibrosis while preserving host defense integrity.
BIOMEDICAL TRANSLATION SOURCE
Biomedical Translation Source
Residual inflammatory pathology observed in advanced cystic fibrosis despite CFTR correction.
Ethnobioprospecting Source
This candidate is not directly derived from a single botanical source. Instead, it is a reverse-engineered synthetic API concept informed by SCF analysis of inflammatory regulation systems and supported by ethnopharmacological observations of protease-modulating, tissue-preserving, and anti-inflammatory medicinal species.
Supporting ethnomedical inspiration includes:
- Uncaria tomentosa (Amazon Basin)
- Croton lechleri (Amazon Basin)
- Copaifera spp.
- Himatanthus sucuuba
These species demonstrate inflammatory regulation and tissue-preservation activities relevant to neutrophil-mediated tissue injury.
SOURCE DESCRIPTION
Traditional Functional Themes
Amazonian Medicine
Observed therapeutic themes:
- Chronic inflammatory conditions
- Wound repair
- Tissue preservation
- Immune balancing
- Fibrotic control
Biomedical Translation
Traditional Concept → SCF Translation
Traditional Observation | Biomedical Translation |
Excess tissue degradation | Protease overactivity |
Chronic inflammatory injury | Neutrophilic inflammation |
Delayed tissue repair | ECM destruction |
Persistent disease recurrence | Self-sustaining inflammatory loops |
SOURCE REGION
Primary Region
Amazon Basin
Ethnomedical Systems
- Amazonian Curanderismo
- Indigenous South American medicinal systems
- Regional anti-inflammatory botanical traditions
Referenced within SCF ethnomedical mapping systems.
THEORY
SCF Therapeutic Innovation Theory
Current cystic fibrosis therapies primarily correct ion transport abnormalities.
However, a major residual disease driver remains:
Protease-Mediated Structural Collapse
Persistent neutrophilic inflammation results in:
- Elastase overproduction
- ECM degradation
- Bronchiectatic progression
- Fibrotic remodeling
The SCF hypothesis proposes that:
Selective pulmonary modulation of neutrophil elastase can interrupt the airway destruction loop while preserving sufficient innate immune competence.
HYPOTHESIZED API THERAPEUTIC CONCEPT
SCF Decentralized Biological Intelligence Hypothesis
Cystic fibrosis progression is not solely a CFTR defect.
Disease expansion emerges from:
- Biofilm persistence
- Protease dysregulation
- ECM destabilization
- Chronic inflammatory amplification
AEROVIA-201 targets the dominant proteolytic node responsible for progressive structural failure.
Expected outcomes:
- Reduced airway destruction
- Reduced inflammatory amplification
- Preservation of lung architecture
- Improved responsiveness to existing therapies
API NAME
Generic Development Name
AEROVIA-201
Scientific Designation
Pulmonary Neutrophil Elastase Regulatory Modulator
API INDEX CODE
SCF-CF-API-201
Registry Classification
SCF-PPRM-CF-201-A01
SCF API TYPE CLASSIFICATION
Mechanistic Class
Protease Regulatory Therapeutic
SCF Therapeutic Classification
Classification Axis | Assignment |
Target Modulator | Moderate |
Safety Harmonizer | Primary |
Metabolic Regulator | Secondary |
Resistance Prevention | Secondary |
Restorative Agent | Moderate |
BIOACTIVITY CLASSIFICATION
Primary Activity
Neutrophil elastase modulation
Secondary Activities
- MMP network stabilization
- ECM preservation
- Inflammatory amplification reduction
Tertiary Activities
- Reduction of fibrotic signaling
- Preservation of epithelial integrity
MOLECULE IDENTIFICATION
Candidate Type
Novel synthetic small molecule
Intended Characteristics
Property | Goal |
MW | 350–550 Da |
Solubility | Moderate–High |
Pulmonary Retention | High |
Systemic Exposure | Low |
Protein Binding | Moderate |
Inhalation Compatible | Yes |
CHEMICAL STRUCTURE CLASSIFICATION
Structural Class
Hypothetical heterocyclic protease-binding scaffold
Pharmacophore Requirements
- Catalytic pocket interaction
- Selective elastase affinity
- Pulmonary retention optimization
- Low systemic permeability
Status
Structure not yet discovered.
Medicinal chemistry campaign required.
PHYTOCHEMICAL ACTIVITY TRANSLATION
The API is not a phytochemical itself.
It is a synthetic pharmaceutical candidate inspired by:
Botanical Source | Relevant Activity |
Uncaria tomentosa | NF-κB modulation |
Croton lechleri | Tissue repair |
Copaifera spp. | Inflammation reduction |
Himatanthus sucuuba | Fibrotic regulation |
API ENGINEERING BLUEPRINT
SCF Functional Assignment
Primary Role
Safety Harmonizer
Secondary Role
Restorative Modulator
Tertiary Role
Resistance Prevention Support
API SCAFFOLD DESIGN STRATEGY
Design Objectives
Domain 1
High-affinity elastase interaction
Domain 2
Minimal activity against:
- Proteinase 3
- Cathepsin G
- Trypsin
- Chymotrypsin
Domain 3
Localized pulmonary exposure
TRI-RADIAL TORUS OVERLAY RATIONALE
Axis A — Target Engagement
Neutrophil elastase
Axis B — Structural Preservation
ECM protection
Axis C — Disease Modification
Inflammatory amplification suppression
Result:
Simultaneous stabilization of the inflammatory–structural–functional axis.
PHARMACOKINETIC ENGINEERING
Delivery System
Primary:
Dry Powder Inhalation (DPI)
Secondary:
Liposomal aerosol
Release Profile
Target:
8–24 hour pulmonary residence
Stability Objectives
- Moisture resistant
- Nebulization compatible
- Shelf stability >24 months
PHARMACOLOGICAL MECHANICS
Mechanism of Action (MeA)
Selective modulation of neutrophil elastase catalytic activity within pulmonary tissues.
Expected downstream effects:
- Reduced elastin degradation
- Reduced proteolytic tissue injury
- Reduced inflammatory amplification
Mode of Action (MoA)
Localized suppression of excessive protease activity while maintaining baseline host-defense function.
SCF FIVE PRINCIPLE ALIGNMENT
Principle | Alignment |
Targeted Drug Action | High |
Pharmacokinetic Optimization | High |
Metabolic Efficiency | Moderate |
Resistance Prevention | Moderate |
Safety Profile | High |
Based on SCF core principles.
PRELIMINARY SYNERGY EVALUATION
TSSM (TriAxis Synergy Score)
Projected: High
Rationale
Addresses:
- Structural damage
- Inflammatory amplification
- Functional decline
HSV-F²
Projected: High
Rationale
Localized lung exposure reduces systemic energetic burden.
SV-EQ
Projected: High
Rationale
Strong target specificity.
MGIS
Projected: Moderate–High
Rationale
Pulmonary delivery supports PK coherence.
SPCI
Projected: High
Rationale
Strong disease-specific phenotypic relevance.
Based on SCF synergy framework definitions.
TRANSLATIONAL DEVELOPMENT PACKAGE
Target Population
Cohort A
CF patients on CFTR modulators with persistent inflammation.
Cohort B
Advanced lung disease.
Cohort C
Modulator non-responders.
BIOMARKER PANEL
Primary
- Neutrophil elastase
- IL-8
- MMP-9
Secondary
- TGF-β
- CRP
- FEV1
Exploratory
- Proteomics
- ECM turnover markers
- Exosomal signatures
PRECLINICAL DEVELOPMENT PRIORITIES
In Vitro
- Elastase inhibition assays
- CF epithelial models
- Air-liquid interface cultures
Ex Vivo
- CF sputum systems
- Lung organoids
In Vivo
- CF rodent models
- Ferret CF models
- Pig CF models
FDA DEVELOPMENT PATHWAY
Regulatory Route
IND → Phase I → Phase II → Phase III → NDA
Potential Designations:
- Orphan Drug Designation
- Fast Track Designation
- Breakthrough Therapy (if supported by clinical evidence)
Consistent with FDA development frameworks.
STAGE GATE RECOMMENDATION
Development Status
Lead Candidate Nominated
Readiness Level
Preclinical Discovery Candidate
Advancement Requirement
Must successfully complete:
- Hit identification
- Lead optimization
- PK/PD characterization
- Exploratory toxicology
- IND-enabling studies
MASTER REGISTRY INDEX
SCF-CF-API-201 — AEROVIA-201 Pulmo-Protease Regulatory Modulator
SCF-CF-S5-0001 — Candidate Nomination Program
SCF-CF-S6-0001 — Candidate Validation Program
SCF-API-DP-0001 — SCF API Discovery Profile Framework
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-PATH-UT-0001 — SCF Pathophysiology Protocol
SCF-FDA-IND-0001 — FDA Translational Development Framework
SCF-PPRM-0001 — Pulmo-Protease Regulatory Modulator Class Registry